| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-03 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate |
2014-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93dc0cac3776538aa84b3dfc346c3379 |
| publicationDate |
2016-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160010186-A |
| titleOfInvention |
Use of HPV E7 truncated peptide for diagnostic and treatment of cervical cancer |
| abstract |
The present invention relates to a composition for treating cervical cancer comprising E7 peptide of HPV type 18 as an active ingredient or a diagnostic composition using the same. When the peptide of the present invention is used as a vaccine for treating cervical cancer, it is possible to overlap with four types of HLA classes (HLA-A * 0201, A * 2402, A * 1101 and A * Is expected to be greatly utilized. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200087899-A |
| priorityDate |
2014-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |